Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

76.81USD
20 Jan 2017
Change (% chg)

$-0.03 (-0.04%)
Prev Close
$76.84
Open
$77.00
Day's High
$77.41
Day's Low
$76.49
Volume
1,644,665
Avg. Vol
1,439,957
52-wk High
$83.78
52-wk Low
$64.25

LLY.N

Chart for LLY.N

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)

Overall

Beta: 0.30
Market Cap(Mil.): $84,794.27
Shares Outstanding(Mil.): 1,103.95
Dividend: 0.52
Yield (%): 2.71

Financials

  LLY.N Industry Sector
P/E (TTM): 33.36 29.51 30.38
EPS (TTM): 2.30 -- --
ROI: 8.54 15.44 14.86
ROE: 15.87 16.62 16.28

BRIEF-Colucid Pharmaceuticals says termination fee of $34 mln to be payable to Eli Lilly upon termination

* Colucid Pharmaceuticals - upon termination of deal under specified circumstances, co will be required to pay Eli Lilly termination fee of $34 million Source text (http://bit.ly/2jKbOWp) Further company coverage:

Jan 18 2017

US STOCKS-Wall St falls before earnings and on U.S. policy uncertainty

* Financials off with bond yields day before big banks' 4th-qtr reports

Jan 12 2017

BRIEF-U.S. appeals court rejects Teva appeal in Lilly patent case over Alimta

Jan 12 U.S. Appeals Court rules for Eli Lilly and against Teva Pharmaceutical in Alimta patent case -- court ruling

Jan 12 2017

Halozyme's pancreatic cancer drug succeeds in mid-stage trial

Halozyme Therapeutics Inc said its lead experimental drug, in tandem with therapies from Celgene Corp and Eli Lilly and Co, succeeded in a mid-stage study involving patients with an advanced form of pancreatic cancer.

Jan 05 2017

Trump's corporate tax holiday could spur pharma M&A

U.S. President-elect Donald Trump's plan to incentivize U.S. companies to repatriate their swelling overseas cash piles could spur a new wave of dealmaking in a pharmaceutical industry seeking to buy its way into growth.

Dec 06 2016

US STOCKS-S&P 500 dips with healthcare shares, Dow edges up ahead of holiday

* Dow up 0.1 pct, S&P down 0.1 pct, Nasdaq down 0.3 pct (Updates to late afternoon, adds dateline)

Nov 23 2016

BRIEF-Eli Lilly and CO incoming CEO David Ricks on CNBC - Amyloid Hypothesis should be continued to be studied in reference to its Alzheimer's drug

* Eli Lilly and CO incoming CEO David Ricks on CNBC - Amyloid Hypothesis should be continued to be studied in reference to its Alzheimer's drug

Nov 23 2016

BRIEF-Paulson & Co cuts share stake in Pfizer, raises share stake in Facebook

* Paulson & Co Inc raises share stake in Facebook Inc by 47.3 percent to 212,700 Class A shares

Nov 14 2016

BRIEF-Eli lilly and Incyte says Baricitinib treatment show improvements in rheumatoid arthritis symptoms in phase 3

* Eli lilly -new analyses of phase 3 trials show improvements in rheumatoid arthritis symptoms following treatment with Baricitinib Source text for Eikon: Further company coverage:

Nov 14 2016

BRIEF-Eli Lilly and Co says new data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes

* New data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes in rheumatoid arthritis patients treated with baricitinib compared to placebo

Nov 02 2016

Competitors

Earnings vs. Estimates